The first-in-class BCMA-directed antibody-drug conjugate belantamab mafodotin-blmf (Blenrep) in combination with carfilzomib (Kyprolis) and dexamethasone (BKd) led to a high overall response rate (ORR) with a tolerable safety profile in patients with... [5612 chars].. reed more
